Definition of lazertinib | 合法藥品大搜索
lazertinib.Anorallyavailablethird-generation,selectiveinhibitorofcertainformsoftheepidermalgrowthfactorreceptor(EGFR)withactivatingmutations, ...
lazertinib. An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, ...
lazertinib中文 Lazertinib Lazertinib vs osimertinib Laser301 Amivantamab lazertinib Amivantamab vmjw Lazertinib Janssen NCT02609776 lazertinib中文 Lazertinib Lazertinib vs osimertinib Laser301 Amivantamab lazertinib Amivantamab vmjw Lazertinib Janssen NCT02609776 磷酸鈣食品 強生製藥董事長 aminophylline心跳 止敏吐價錢 ibuprofen牙痛 Amoxicillin 500mg 用法 大塚製藥h軟膏 暈 速寧
Lazertinib in patients with EGFR mutation | 合法藥品大搜索
由 MJ Ahn 著作 · 2019 · 被引用 45 次 — Lazertinib (YH25448) is an oral, highly potent, irreversible, third-generation, mutant-selective, and wild-type-sparing EGFR TKI, with half maximal ... Read More
Lazertinib | 合法藥品大搜索
由 S Dhillon 著作 — Lazertinib (LECLAZA®) is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Yuhan and ... Read More
Definition of lazertinib | 合法藥品大搜索
lazertinib. An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, ... Read More
Clinical Trials Using Lazertinib | 合法藥品大搜索
NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying lazertinib. Read More
Updated Amivantamab and Lazertinib Combination Data ... | 合法藥品大搜索
2021年5月19日 — Lazertinib is an oral, third-generation, brain-penetrant, EGFR TKI that targets both the T790M mutation and activating EGFR mutations while ... Read More
ESMO 2020 肺癌亮點:osimertinib 降低腦轉移風險達8 成 ... | 合法藥品大搜索
2020年9月21日 — Amivantamab 和lazertinib 聯合一線治療EGFRm NSCLC 反應率達100% ... 接受amivantamab 和lazertinib 治療的患者,在追蹤7 個月中位數(4-7 ... Read More
A Study of Lazertinib as Monotherapy or in Combination With ... | 合法藥品大搜索
An arm type in which a group of participants does not receive any intervention/treatment during the clinical trial. Observational study. A type of clinical study in ... Read More
A Study of Amivantamab and Lazertinib Combination Therapy ... | 合法藥品大搜索
2020年7月27日 — Osimertinib and Lazertinib are EGFR tyrosine kinase inhibitors (TKIs). Amivantamab is a novel bispecific antibody that targets the extracellular ... Read More
Lazertinib | ≥99%(HPLC) | 合法藥品大搜索
Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for ... Read More
相關資訊整理
【癌能畢 膜衣錠90毫克】適用於治療ALK陽性的晚期非小細胞肺癌(NSCLC)病人。
藥品名稱:癌能畢膜衣錠90毫克許可證字號:衛部藥輸字第027731號許可證種類:製 劑適應症:適用於治療ALK陽性的晚期非小細胞肺...
【癌能畢 膜衣錠180毫克】適用於治療ALK陽性的晚期非小細胞肺癌(NSCLC)病人。
藥品名稱:癌能畢膜衣錠180毫克許可證字號:衛部藥輸字第027732號許可證種類:製 劑適應症:適用於治療ALK陽性的晚期非小細胞肺...
【癌能畢 膜衣錠30毫克】適用於治療ALK陽性的晚期非小細胞肺癌(NSCLC)病人。
藥品名稱:癌能畢膜衣錠30毫克許可證字號:衛部藥輸字第027730號許可證種類:製 劑適應症:適用於治療ALK陽性的晚期非小細胞肺...
【安立適膠囊150毫克】ALECENSA®適用於治療ALK陽性的晚期非小細胞肺癌(NSCLC)患者。
藥品名稱:安立適膠囊150毫克許可證字號:衛部藥輸字第027028號許可證種類:製 劑適應症:ALECENSA®適用於治療ALK陽性的晚期非...
【立克癌 膠囊 150 毫克】治療ALK陽性的晚期非小細胞肺癌患者。治療前須經合適之檢驗方式測得ALK陽性。
藥品名稱:立克癌膠囊150毫克許可證字號:衛部藥輸字第026674號許可證種類:製 劑適應症:治療ALK陽性的晚期非小細胞肺癌患者。...
【秘配得 凍晶注射劑4毫克】適應症適用於兒童、青少年與年輕成人,治療經由肉眼可見下完整手術切除後之高度可切除之非轉移性骨肉瘤(high-grade resectable non-metastatic osteosarcoma after maroscopically complete surgical resection)。其使用係與手術後之多重藥物化學療法併用。
藥品名稱:秘配得凍晶注射劑4毫克許可證字號:衛部藥輸字第026319號許可證種類:製 劑適應症:適應症適用於兒童、青少年與年輕...